Introduction
In this issue, Woosley et al. [1] describe an important tool for use in clinical decision making about drugs associated with a risk of Torsades de pointes (TdP), a life-threatening ventricular tachyarrhythmia specifically defined by its characteristic electrocardiographic (ECG) profile. Their work is particularly useful for clinicians and patients because drugs are assigned to categories according to their risk of TdP via the integrated approach, ''Adverse Drug Event Causality Analysis'' (ADECA). This approach combines updated information from published and unpublished data (mainly disproportionality analysis of major international spontaneous reporting systems). ''CredibleMeds.org'' is a website through which it is possible to freely (only registration required) view categories of drugs with torsadogenic potential: known TdP risk, possible TdP risk, conditional TdP risk, and drugs to be avoided in patients with long QT syndrome.
TdP is a well-described clinical condition, known as a designated medical event in pharmacovigilance. It is typically associated with QT prolongation and can lead to sudden cardiac death (SCD) when it degenerates into ventricular fibrillation [2] . However, as the spectrum of events is seldom observed in its entirety, the diagnosis can only be guessed, not proved, in many cases (e.g., in a patient with SCD a few days after starting a new drug). QT prolongation is relatively common and is a prerequisite for TdP, whereas TdP itself is very rare. The important gap in knowledge relates to how the two are linked. Moreover, drugs such as verapamil can cause QT prolongation with minimal or no observed cases of TdP. Thus, this is a grey area in which a surrogate marker of toxicity (QT prolongation) is extensively documented and largely used by regulators during drug development, but assessing the actual risk of TdP in a single patient is difficult. A tool to assist in clinical decision making is particularly important in areas such as this.
The Regulators' View
It is important to recapitulate the past 25 years of debate: evidence on the proarrhythmic potential of QT-prolonging drugs has grown exponentially since the early 1990s, when a number of frequently used medicines started to become subject to regulatory restriction/withdrawal because of their proarrhythmic risk. Antihistamines, antipsychotics, and prokinetics were the most frequently involved classes, with well-known examples being astemizole, cisapride, haloperidol, and terfenadine. These regulatory measures usually resulted from case reports of drug-induced TdP, but its extreme rarity, the many risk factors, and under-recognition mean that not all truly torsadogenic drugs have been systematically identified.
As a general approach, the first step in detecting a specific adverse drug reaction includes defining the main clinical event, together with its possible clinical and preclinical proxies in increasing order of sensitivity. This is the case for TdP, since it is a clearly diagnosed event and QT prolongation is its recognized sub-clinical proxy. Moreover, in vitro electrophysiological studies are considered a useful tool to identify ion channel-blocking properties (K ? , Na ?? , and Ca ?? ), which provide less predictive but more reproducible information on torsadogenic potential [3] . When applying this strategy to a large set of drugs, one must keep in mind that only a few will have a significant association with TdP. This is why the US FDA, in particular, focuses on clinical studies (thorough QT [TQT] studies) and largely disregards preclinical evidence, which is less reliable because of its low predictive value and the risk of excluding useful drugs from development.
Ethics and the rarity of TdP preclude prospective trials on the risk of TdP. Therefore, investigations of possible associations must resort to a pharmacoepidemiological approach. One strategy to increase the sensitivity of methods to detect torsadogenic potential is to try to capture other clinical entities that are strictly related to TdP, such as SCD (or even sudden death), which represents the outcome in cases of fatal TdP [4] . On one hand, this composite endpoint strongly decreases specificity, and many experts do not consider it useful in the evaluation of the torsadogenic potential of drugs (e.g., SCD is more frequently associated with coronary events as well as strokes, pulmonary embolism, and aneurysm complications) since multiple mechanisms underlie this risk and no single preclinical model can be developed for high-throughput screening [5] . On the other hand, other experts prefer to define proarrhythmic risk by pooling the most severe events: TdP, SCD, and ventricular arrhythmia [6] . The latter approach allows the identification of a higher number of clinically significant cases, with the opportunity to calculate odds ratios or disproportionality despite the aforementioned specificity limitations. The fact that drugs can promote SCD through many other arrhythmic (and even non-arrhythmic) mechanisms should be carefully considered (Fig. 1) . This was the approach followed by the EUfunded ARITMO project (http://cordis.europa.eu/project/ rcn/94061_en.html) [7] .
In conclusion, from the regulatory viewpoint, the different types of evidence described have different roles as possible measures to limit population-level risk: (1) for marketed drugs, when drug-attributable TdP (or SCD) cases are identified, the overall risk-benefit profile should be evaluated, including their place in therapy and available alternatives; (2) for drugs under development, a positive response to in vitro (and even in silico) test batteries could be sufficient to slow the overall process toward clinical application. More predictive approaches are currently under development by regulators: specific ECG assessments in phase I clinical trials could confirm signals from preclinical tests and allow progress towards marketing authorization [8] .
The Prescribers' View
Prescribers may easily consult CredibleMeds.org when they are selecting drugs for patients, especially if they have risk factors for TdP (previous arrhythmia, multiple drug therapy, electrolyte imbalance, among others) [9] . If the drug of interest belongs to one of the lists, therapeutic alternatives should be considered so as to avoid a lifethreatening event.
Although this tool is limited by a lack of direct information on safe alternatives, the authors recently introduced useful additional information for some drugs not included in the lists. For example, ''not classified'' drugs are agents that can be alternatively evaluated by the board and for which ''the evidence available at that time did not result in a decision for it to be placed in any of the four QT risk categories'' (e.g., fluphenazine) or ''under review'' (e.g., sofosbuvir). However, many drugs are actually not considered at all, at least thus far, because no ''white list'' is provided. It should be recognized that this aim is intrinsically difficult to achieve, not least because of legal issues.
To exemplify the usefulness of the approach by Woosley et al. [1] in this difficult area, we describe a couple of examples. The first is the peculiar scenario of antipsychotics, as presented in Table 1 . Although, in clinical practice, the first step in drug selection within this therapeutic class is represented by the specific pharmacological profile of the single agent (first vs. second generation) among those available for a given administration route (intravenous vs. oral or depot) and setting of care (hospital vs. ambulatory), patients with risk factors for TdP could first be approached with agents in the bottom category, given their hypothetically safer profile, reinforced by a lengthy marketing life.
In the area of antibacterials, fluoroquinolones deserve specific mention. All agents are in fact considered at risk: ciprofloxacin, moxifloxacin, levofloxacin, and gatifloxacin are classified as ''known risk'', and norfloxacin and ofloxacin are classified as ''possible risk''. Should the prescriber definitely avoid this class in patients with predisposing conditions? Or should additional effort be made to compare single agents on the basis of a personal literature review, for instance by looking for analytical studies or systematic reviews? Information on the ''strength of evidence'' should be added to the classification of risk for each drug to increase its application in clinical practice. This important ''label'' would also indirectly bridge the gap of the missing white list. The ability to search the lists in terms of pharmacological classes (e.g., using the anatomical therapeutic chemical [ATC] classification of drugs established by the World Health Organization [http://www. whocc.no/atcddd]) could also provide an additional aid for rapid clinical consultation.
The Researchers' View
Researchers have also used CredibleMeds.org lists to plan analytical studies on the proarrhythmic risk of recent drugs. Experts working on drug-induced TdP (e.g., when validating a pre-clinical model or setting up an observational study) have different opinions on using these lists to identify drugs with strong torsadogenic potential to create the reference set of drugs. In fact, the first includes different pharmacological classes with very diverse pro-arrhythmic risk (from class III antiarrhythmic agents, such as sotalol, to antibacterials such as ciprofloxacin). Moreover, the absence of information on the strength of the evidence limits the value of these lists.
Other algorithms and relevant rankings of torsadogenic drugs are available in the literature. Most approaches involve preclinical assays defined on the basis of training sets of drugs with clinical evidence of TdP. Their main role would be the early identification of torsadogenic properties during the preclinical phases of drug development. Although in many cases authors claim a high level of predictivity, the lists are inconsistent, such that a drug can simultaneously be listed both as torsadogenic and as not torsadogenic, depending on the list [10] . Substantial funds have been devoted to research and regulatory activities in the last 2 decades to define risky categories and methods for early prediction of torsadogenicity, but many gray areas persist [11] . In some particular fields, including oncology, the proarrhythmic risk of drug therapy is considered acceptable in view of the possible outcomes of the underlying disease. The true incidence of SCD in oncological patients is unknown, but it is known to present a cluster of [14] . Very recently, Bjornsson and Hoofnagle [15] created drug categories based on the number of published case reports. We encourage the authors of LiverTox to implement an approach similar to that of ADECA to assign drugs to risk categories, for instance by combining published evidence with unpublished real-time data from international spontaneous reporting systems, thus supporting the needs of both clinical practice and patients.
In conclusion, Woosley et al. [1] should be commended for the effort they are putting into reducing the gap between pathophysiological knowledge and clinical practice in the area of drug-induced arrhythmia as well as providing insights applicable to drug safety research. Further steps towards optimization of their tool in clinical practice could include (1) building a search strategy by therapeutic class; (2) creating a white list category for drugs that show no proarrhythmic potential after long and widespread use; and (3) sharing the strength of the evidence underpinning the assignment of each drug to a particular category.
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